Syenex

Syenex develops cell-specific delivery systems and programmable cell engineering payloads for biotechnology and drug development applications. The company creates optimized enveloped vector surface compositions for high-efficiency, cell type-specific delivery, compatible with a variety of programmable cell engineering payload types. Syenex offers best-in-class delivery solutions for the most impactful therapeutic cell types, with technologies designed for scale including CDMO integrations and regulatory support to streamline development from pre-clinical prototyping through clinical validation. The company provides universal access to a continuously improving catalog of cell engineering and delivery technologies, serving drug developers working on cell and gene therapies and other advanced therapeutics. Founded in 2022 and headquartered in Chicago, United States, Syenex has raised approximately $13.7 million in Series B funding from investors including AlleyCorp and KdT Ventures.